BCLI on OTC
BRAINSTORM CELL THERAPEUTICS INC.
Price unavailable
Last updated Oct 16, 2026.
Overview
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Financial statements
Every line of the income statement in the latest annual report, as filed.8
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Research and development | $4.2M | $4.7M |
| General and administrative | $5.8M | $7.0M |
| Operating loss | -$10.0M | -$11.7M |
| Financial expense, net | $533.0K | $77.0K |
| Gain on change in fair value of Warrants liability (Note 7) | $179.0K | $147.0K |
| Net loss | -$10.3M | -$11.6M |
| Basic net loss per share (in dollars per share) | -$1.11 | -$2.31 |
| Diluted net loss per share (in dollars per share) | -$1.11 | -$2.31 |
| Weighted average number of shares outstanding used in computing basic net loss per share (in shares) | 9.3M shares | 5.0M shares |
| Weighted average number of shares outstanding used in computing diluted net loss per share (in shares) | 9.3M shares | 5.0M shares |
Every line of the balance sheet in the latest annual report, as filed.8
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $29.0K | $187.0K | |
| Other accounts receivable | $86.0K | $63.0K | |
| Prepaid expenses and other current assets | $192.0K | $135.0K | |
| Total current assets | $307.0K | $385.0K | |
| Other long-term assets | $25.0K | $22.0K | |
| Restricted Cash | $247.0K | $184.0K | |
| Operating lease right of use asset (Note 4) | $208.0K | $807.0K | |
| Property and Equipment, Net (Note 5) | $235.0K | $434.0K | |
| Total Long-Term Assets | $715.0K | $1.4M | |
| Total assets | $1.0M | $1.8M | |
| Accounts payables | $7.1M | $6.1M | |
| Accrued expenses | $396.0K | $619.0K | |
| Short-term loans (Note 11) | $967.0K | $300.0K | |
| Operating lease liability (Note 4) | $208.0K | $549.0K | |
| Employees related liability | $2.4M | $1.4M | |
| Total current liabilities | $11.0M | $9.0M | |
| Operating lease liability (Note 4) | $171.0K | ||
| Warrants liability (Note 7) | $0 | $447.0K | |
| Total long-term liabilities | $618.0K | ||
| Total liabilities | $11.0M | $9.6M | |
| Common Stock of $0.00005 par value - Authorized: 250,000,000 shares at December 31, 2025 and 100,000,000 shares at December 31, 2024 respectively; Issued and outstanding: 11,034,775 and 6,141,762 shares at December 31, 2025 and December 31, 2024 respectively | $16.0K | $14.0K | |
| Additional paid-in-capital | $227.1M | $219.0M | |
| Treasury stocks | -$116.0K | -$116.0K | |
| Accumulated deficit | -$236.9M | -$226.6M | |
| Total stockholders' deficit | -$10.0M | -$7.8M | -$4.9M |
| Total liabilities and stockholders' deficit | $1.0M | $1.8M | |
| Common Stock, par value (in dollars per share) | $0.00 | $0.00 | |
| Common Stock, shares authorized | 250.0M shares | 100.0M shares | |
| Common Stock, shares issued | 11.0M shares | 6.1M shares | |
| Common Stock, shares outstanding | 11.0M shares | 6.1M shares |
Every line of the cash flow in the latest annual report, as filed.8
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -$10.3M | -$11.6M |
| Depreciation | $199.0K | $240.0K |
| Stock-based compensation related to options granted to employees and directors | $1.5M | $750.0K |
| Change in operating lease liability, net | $87.0K | $54.0K |
| Decrease (increase) in prepaid expenses and other accounts receivable | -$83.0K | $401.0K |
| Increase (decrease) in trade payables | $987.0K | $1.1M |
| Increase in accrued expense | $85.0K | |
| Gain on change in fair value of warrants (Note 7) | -$179.0K | -$147.0K |
| Increase (decrease) in employees related liability and accrued expenses | $716.0K | $106.0K |
| Total net cash used in operating activities | -$7.0M | -$9.1M |
| Purchase of property and equipment | $12.0K | |
| Total net cash provided by investing activities | $12.0K | |
| Proceeds from issuance of shares in at-the-market (ATM) offering (Note 8) | $4.3M | $4.3M |
| Proceeds from Issuance of shares for private placement (Note 8) | $3.6M | |
| Proceeds from short-term loans (Note 11) | $582.0K | |
| Proceeds from warrants issuance (Note 7) | $1.5M | |
| Debt-for-Equity Swap | $450.0K | |
| Total net cash provided by financing activities | $6.9M | $8.0M |
| Decrease in cash and cash equivalents | -$95.0K | -$1.1M |
| Reclassifying the warrants liabilities to equity (Note 8) | $268.0K |
Compare BRAINSTORM CELL THERAPEUTICS INC. with another company
Former names
Recent filings
- Aug 14, 20268-K
- Aug 14, 202610-Q
- Jul 30, 20268-K
- Jul 28, 20264 OWNERSHIP DOCUMENT
- Jul 28, 20264 OWNERSHIP DOCUMENT
- Jun 3, 20263 OWNERSHIP DOCUMENT
- Jun 2, 2026EFFECT
- Jun 1, 2026CORRESP
- May 29, 20264 OWNERSHIP DOCUMENT
- May 29, 20264 OWNERSHIP DOCUMENT
- May 29, 20264 OWNERSHIP DOCUMENT
- May 29, 20264 OWNERSHIP DOCUMENT
- May 29, 20264 OWNERSHIP DOCUMENT
- May 28, 20268-K
- May 27, 2026UPLOAD
Every filing from the last three years, summarized. The full record is on SEC EDGAR.1
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10